Investigational Drug Information for CB-839
✉ Email this page to a colleague
What is the development status for investigational drug CB-839?
CB-839 is an investigational drug.
There have been 21 clinical trials for CB-839.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2017.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are seventeen US patents protecting this investigational drug and one hundred and seventy-four international patents.
Summary for CB-839
| US Patents | 17 |
| International Patents | 174 |
| US Patent Applications | 74 |
| WIPO Patent Applications | 41 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2017-09-06) |
| Vendors | 53 |
Recent Clinical Trials for CB-839
| Title | Sponsor | Phase |
|---|---|---|
| CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients | University of Alabama at Birmingham | Phase 1 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
| Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects | Novotech (Australia) Pty Limited | Phase 1 |
Clinical Trial Summary for CB-839
Top disease conditions for CB-839
Top clinical trial sponsors for CB-839
US Patents for CB-839
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CB-839 | See Plans and Pricing | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | See Plans and Pricing |
| CB-839 | See Plans and Pricing | Compositions and methods of treating cancer harboring PIKC3A mutations | Case Western Reserve University (Cleveland, OH) | See Plans and Pricing |
| CB-839 | See Plans and Pricing | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Calithera Biosciences, Inc. (South San Francisco, CA) | See Plans and Pricing |
| CB-839 | See Plans and Pricing | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | See Plans and Pricing |
| CB-839 | See Plans and Pricing | Crystal forms of glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CB-839
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CB-839 | China | CN109982703 | 2036-08-25 | See Plans and Pricing |
| CB-839 | European Patent Office | EP3503893 | 2036-08-25 | See Plans and Pricing |
| CB-839 | Japan | JP2019524852 | 2036-08-25 | See Plans and Pricing |
| CB-839 | World Intellectual Property Organization (WIPO) | WO2018039441 | 2036-08-25 | See Plans and Pricing |
| CB-839 | Australia | AU2016335991 | 2035-10-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
